Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Oktober 2025 07:00 ET | Quelle: Eccogene Inc

Eccogene Receives U.S. FDA Clearance to Initiate Phase 2a MOSAIC Trial of ECC4703 and ECC0509 for MASH

BOSTON and SHANGHAI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic...
18. Juni 2025 07:00 ET | Quelle: Eccogene Inc

Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China

BOSTON and SHANGHAI, June 18, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic...
17. Juni 2025 07:00 ET | Quelle: Eccogene Inc

Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide

BOSTON and SHANGHAI, June 17, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic...
01. Mai 2025 07:00 ET | Quelle: Eccogene Inc

Eccogene Appoints Dr. Jai Patel as Chief Medical Officer

BOSTON and SHANGHAI, May 01, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and...
07. Januar 2025 07:00 ET | Quelle: Eccogene Inc

Eccogene Announces Formation of Scientific Advisory Board

BOSTON and SHANGHAI, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic...
15. November 2024 11:00 ET | Quelle: Eccogene Inc

Eccogene Announces Positive Phase 1 Data for Oral THR-β Full Agonist and Oral SSAO Inhibitor in Late-Breaking Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®

BOSTON and SHANGHAI, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic...
23. Oktober 2024 07:00 ET | Quelle: Eccogene Inc

Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetes

BOSTON, Mass. and SHANGHAI, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic...
05. September 2024 08:00 ET | Quelle: Eccogene Inc

Eccogene Appoints Glenn Reicin as Chief Financial Officer

BOSTON, Mass. and SHANGHAI, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic...